Janone regains compliance with nasdaq's listing requirements

Las vegas, march 15, 2024 /prnewswire/ -- janone (nasdaq: jan), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, today announced that on march 13, 2024 it received a notification letter from the listing qualifications staff of the nasdaq stock market inc. ("nasdaq") indicating that the company had regained compliance with the minimum bid price requirement set forth in rule 5550(a)(2) of the nasdaq listing rules (the "minimum bid price requirement"). as previously announced, the company received a notification letter from nasdaq on september 11, 2023, indicating that the closing bid price per share had been below $1.00 for a period of 30 consecutive business days and that the company did not meet the minimum bid price requirement.
JAN Ratings Summary
JAN Quant Ranking